We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Alex Herrera, MD
Alison J. Moskowitz, MD
Late-Stage Bispecifics and ADCs in DLBCL
Sarah Rutherford, MD
John P. Leonard, MD
Application of Data from the ECHELON-1 Trial
Individualizing Frontline Treatment
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Kami Maddocks, MD
Matthew J. Matasar, MD
Antibody-Drug Conjugates in FL
Bispecific Antibodies in FL
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
NCCN Guideline Updates in DLBCL
Patient Selection for ADCs in First-Line DLBCL
Case 2: In a Patient With PD-L1 1–49%, Should I Use Single Agent IO or Combination IO?
Charu Aggarwal, MD, MPH
Joshua E. Reuss, MD
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Case 1: How Should I Choose Between Single-Agent IO or IO/Chemotherapy in Patients With PD-L1 = 50% and No Driver Mutations?
NSCLC Case by Case: Optimizing 1L Immunotherapy for Advanced & Metastatic Disease
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education